Keith Dunleavy vs August Troendle Net Worth: $4.6B vs $4.4B

Quick answer

Keith Dunleavy ($4.6 billion, rank #375) is richer than August Troendle ($4.4 billion, rank #396) — by about $200 million, or roughly 5%. But the comparison is the interesting part: both are American physicians who founded healthcare companies, both debuted on the September 2026 Forbes 400 as newcomers, and their ranks sit just 21 spots apart. Dunleavy is the Harvard MD who built Inovalon over 26 years, sold it for $7.3 billion in 2021, and rode a pre-IPO SpaceX bet into the list. Troendle is the University of Maryland MD who founded the clinical research firm Medpace in Cincinnati in 1992 and still runs it as president and CEO. For Dunleavy's full story, see Keith Dunleavy's net worth.

Head-to-head: the numbers

The $200 million gap is modest, but its composition is not. Troendle's wealth is essentially one thing — his Medpace shareholding as an operating CEO. Dunleavy's is two things: the Inovalon stake plus the Apandion portfolio. That second engine is why Dunleavy pulled ahead.

Two doctors, two companies

The parallel careers are striking. Dunleavy earned his MD from Harvard, completed an internal medicine residency at Johns Hopkins, conceived Inovalon during that residency, and became CEO in 1998 — building a cloud data-analytics platform for health plans and hospitals. Troendle earned his MD from the University of Maryland School of Medicine, worked on cholesterol-drug development at Sandoz, served as a medical review officer in the FDA's Division of Metabolic and Endocrine Drug Products, and founded Medpace in Cincinnati in 1992 — a clinical research organization running trials for drugmakers.

Both chose the picks-and-shovels layer of healthcare: data, analytics, and trial services rather than drug discovery. Both stayed with their companies for decades. The difference is that Dunleavy's company went through a full public-market cycle — 2015 IPO, 2021 take-private — while Troendle never left the operator's chair.

How Dunleavy pulled ahead

Dunleavy's edge comes from the second act. After the $7.3 billion Inovalon sale in 2021 — in which he rolled most of his ~64% pre-deal stake into the private company, keeping about 15% — he founded Apandion, a self-funded investment firm. Forbes says Apandion became a pre-IPO backer of SpaceX, and the rocket company's blockbuster June 2026 IPO crystallized that stake's value. Coverage of the 2026 Forbes 400 newcomers explicitly tied Dunleavy's debut to the SpaceX position.

Troendle has no second act — he does not need one. He is still building Medpace, and his ~20% holding does the compounding. But in a year when the Forbes 400 cutoff rose to $4.4 billion, Troendle cleared the bar by the slimmest of margins while Dunleavy's diversified base gave him $200 million of clearance. The operator-vs-allocator split is the whole story of the gap.

The operator vs. the allocator

Frame the comparison as a strategy debate. Troendle is the pure operator: one company, 34 years (1992–2026), still CEO, wealth concentrated in the business he runs every day. Dunleavy was the operator for 26 years (1998–2025), then became the allocator: a board seat at Inovalon, a self-funded firm, founder-led tech bets. Neither approach is obviously better — Troendle's concentration gives him control; Dunleavy's diversification gave him the 2026 edge.

There is a salary footnote, too. Dunleavy famously took a $205,000 base salary with no bonus or equity by choice — his wealth was always the stake. (See Keith Dunleavy's salary.) Troendle's compensation as a sitting public-company-style CEO is a different matter, but the principle both men share is the same: the fortune is the ownership, not the paycheck.

The 2026 debut club

Dunleavy and Troendle did not just land near each other on the list — they arrived together. The 2026 Forbes 400 welcomed 34 newcomers, and healthcare trade coverage singled out both men as first-timers: Dunleavy at #375 with $4.6 billion, Troendle at #396 with $4.4 billion. They were two of the four physician-billionaires on the list, alongside Thomas Frist Jr. ($33.6 billion, #32) and Patrick Soon-Shiong ($10.3 billion, #151).

The bar keeps rising around them. The 2026 cutoff climbed to $4.4 billion — exactly Troendle's figure — which knocked three people off the list entirely. That makes Troendle the last man in and Dunleavy the man with $200 million of breathing room. In a list where the minimum moves every year, the margin between comfortably in and barely in is the difference between a diversified portfolio and a single concentrated stake.

Two paths, one playbook

Zoom out and the two careers read as variations on a single playbook: doctor sees broken system, builds data/services company, holds on for decades. Dunleavy's broken system was fragmented healthcare data, spotted during his Johns Hopkins residency; his answer was Inovalon's analytics platform, built over 26 years. Troendle's broken system was the inefficiency of clinical trials, spotted during his years at Sandoz and the FDA; his answer was Medpace, built over 34 years and counting.

The divergence is what happened after the building. Dunleavy took Inovalon public (2015), sold it ($7.3 billion, 2021), and became an investor — the allocator path. Troendle never sold, never left, and never diversified — the operator path. Dunleavy's Dartmouth profile describes a founder who was "the first one in the office in the morning, and the last one to leave at night"; Troendle's three-decade CEO tenure tells the same story in a different city. Same work ethic, same medical training, same healthcare-services lane — different exit decisions, and a $200 million gap to show for it.

Who wins long-term?

The honest answer: it depends on SpaceX and Medpace. Dunleavy's fortune now moves with two variables — Inovalon's private valuation and SpaceX's public price — while Troendle's moves with one: Medpace. If SpaceX keeps climbing post-IPO, Dunleavy's lead widens. If Medpace compounds as a CRO in a growing trials market, Troendle's concentration could close the $200 million gap. Both men are 2026 debutants with decades of compounding behind them and, in Dunleavy's case, a rocket strapped to the portfolio.

For now, the scoreboard reads $4.6 billion to $4.4 billion — Dunleavy by a nose, Troendle by concentration. Two doctors, two companies, one debut year. For Dunleavy's corporate map, see Keith Dunleavy's companies.

Frequently asked questions